Skip to main content
OpenTrials
Completed

NCT Number: NCT02351180

Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients

The purpose of this study is to determine if the use of inhaled beclomethasone after a community-acquired respiratory viral infection in a lung transplant recipient decreases the risk of the subsequent development of chronic lung allograft dysfunction.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Washington University School of Medicine

St Louis, Missouri, 63110, United States

About this study

Community-acquired respiratory viral (CARV) infections after lung transplantation are associated with an increased risk for the development of chronic lung allograft dysfunction (CLAD) after lung transplantation. The exact mechanisms whereby CARV infections increase this risk are unknown. We propose that viral infection results in airway epithelial cell injury and the expression of injury-response genes that provide signals that initiate immunologic and non-immunologic pathways that result in the airway remodeling characteristic of obliterative bronchiolitis, the predominant pathology of CLAD. Systemic and inhaled corticosteroids are frequently used as anti-inflammatory agents to treat the peribronchiolar inflammation seen in viral bronchiolitis. Beneficial effects from corticosteroids have been reported, but this has not been demonstrated in lung transplant recipients. The aim of this single center, randomized, double blind, placebo controlled study is to evaluate the short and long term effects of a 6 month course of inhaled beclomethasone on adult lung transplant recipients with CARV infection.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult (≥ 18 years old)
  • Single, bilateral, or heart-lung transplant recipient
  • Confirmed infection with a community-acquired respiratory virus including: adenovirus, coronavirus, influenza A or B, respiratory syncytial virus (RSV), parainfluenza virus (PiV), human metapneumovirus (hMPV), and rhinovirus
  • At least 6 months post-transplant, with completion of 6 month bronchoscopy if indicated
  • Able and willing to give written informed consent and comply with study procedures (e.g. testing, treatment)

Exclusion criteria

  • BOS Stage 3
  • Requirement for mechanical ventilation at study entry
  • Use of inhaled steroids at the time of CARV infection
  • Any condition that in the investigator's opinion would preclude the patient's participation in a clinical trial
  • Lack of available spirometric data to establish a baseline forced expiratory volume in 1 second and/or forced vital capacity
  • Pregnancy
  • Current participation in another interventional clinical trial

Treatment and study plan

Inhaled beclomethasone

Drug

Inhaled steroid that may decrease airway inflammation and the risk of chronic rejection

Placebo

Drug

Placebo will serve as a control treatment

Primary outcomes

  1. Number of Participants Free From New or Progressive Chronic Lung Allograft Dysfunction

    Time frame: 180 days

  2. Death

    Time frame: 180 days

Secondary outcomes

  1. Acute Rejection

    Time frame: 180 days

  2. Lymphocytic Bronchiolitis

    Time frame: 180 days

  3. Donor-specific Antibodies

    Time frame: 180 days

  4. Chronic Lung Allograft Dysfunction

    Time frame: 180 days

Sponsors and collaborators

Lead sponsor

Washington University School of Medicine

Other

Registry information

Official study title

A Randomized Placebo Controlled Trial of Inhaled Beclomethasone After Community-acquired Respiratory Viral Infection in Lung Transplant Recipients

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Jan 30, 2015
Registry last updated
Mar 3, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.